• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本严重 COVID-19 患者的髓系细胞动力学与临床结局的相关性。

Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan.

机构信息

Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, Japan.

AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, Japan.

出版信息

Int Immunol. 2021 Mar 31;33(4):241-247. doi: 10.1093/intimm/dxab005.

DOI:10.1093/intimm/dxab005
PMID:33538817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7928855/
Abstract

An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with IL-8 levels, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Our data indicate that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan.

摘要

髓系细胞扩增是严重 2019 冠状病毒病(COVID-19)的标志。然而,关于髓系细胞扩增的数据是在欧洲收集的,那里 COVID-19 的死亡率高于包括日本在内的其他地区。因此,在死亡率较低的地区,COVID-19 诱导的髓系细胞亚群的特征在很大程度上尚不清楚。在这里,我们分析了日本 COVID-19 患者血液样本中髓系来源的抑制细胞(MDSC)亚群的细胞动力学,并研究了它们中的任何一个是否与疾病严重程度和预后相关。我们观察到,多形核(PMN)-MDSC 亚群在严重病例中短暂扩增,但在轻度或中度病例中没有扩增。与欧洲的先前研究相反,该亚群在严重病例的幸存者中选择性扩增,并在出院前消退,但在日本队列中未观察到非幸存者的这种短暂扩增。对血浆细胞因子/趋化因子水平的分析表明,PMN-MDSC 频率与 IL-8 水平呈正相关,表明在严重 COVID-19 发作后,IL-8 参与了 PMN-MDSC 向外周血的募集。我们的数据表明,PMN-MDSC 亚群的短暂扩增导致临床结局改善。因此,该髓系细胞亚群可能是日本严重 COVID-19 病例预后的预测因子。

相似文献

1
Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan.日本严重 COVID-19 患者的髓系细胞动力学与临床结局的相关性。
Int Immunol. 2021 Mar 31;33(4):241-247. doi: 10.1093/intimm/dxab005.
2
Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions.轻度和无症状 COVID-19 恢复期患者表现出与具有调节功能的中性粒细胞亚群相关的长期免疫抑制终末表型。
Front Immunol. 2021 Sep 29;12:748097. doi: 10.3389/fimmu.2021.748097. eCollection 2021.
3
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome.髓系来源的抑制性细胞的早期扩增抑制了 SARS-CoV-2 特异性 T 细胞反应,并且可能预测 COVID-19 的致命结局。
Cell Death Dis. 2020 Oct 27;11(10):921. doi: 10.1038/s41419-020-03125-1.
4
Correlation of myeloid-derived suppressor cells with C-reactive protein, ferritin and lactate dehydrogenase levels in patients with severe COVID-19.重症 COVID-19 患者骨髓源性抑制细胞与 C 反应蛋白、铁蛋白和乳酸脱氢酶水平的相关性。
Scand J Immunol. 2022 Jan;95(1):e13108. doi: 10.1111/sji.13108. Epub 2021 Oct 15.
5
Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19.髓系来源的抑制细胞作为 COVID-19 的潜在生物标志物和治疗靶点。
Front Immunol. 2021 Jun 18;12:697405. doi: 10.3389/fimmu.2021.697405. eCollection 2021.
6
Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients.自噬标志物表达降低和髓系来源抑制细胞扩增与重症 COVID-19 患者 T 细胞反应不良相关。
Front Immunol. 2021 Feb 22;12:614599. doi: 10.3389/fimmu.2021.614599. eCollection 2021.
7
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).骨髓来源的抑制性细胞在重症冠状病毒病(COVID-19)患者中的扩增。
Cell Death Differ. 2020 Nov;27(11):3196-3207. doi: 10.1038/s41418-020-0572-6. Epub 2020 Jun 8.
8
Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.功能性单核细胞来源的髓样抑制细胞在血液中增加,但不在气道中增加,并可预测 COVID-19 的严重程度。
J Clin Invest. 2021 Mar 15;131(6). doi: 10.1172/JCI144734.
9
Elevated frequencies of CD14HLA-DR MDSCs in COVID-19 patients.新冠病毒肺炎患者中CD14+HLA-DR髓系来源抑制细胞频率升高。
Aging (Albany NY). 2021 Feb 26;13(5):6236-6246. doi: 10.18632/aging.202571.
10
Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19.轻度 COVID-19 患者血液中单核细胞来源的髓样抑制细胞增加,但调节性 T 淋巴细胞减少。
Viral Immunol. 2021 Nov;34(9):639-645. doi: 10.1089/vim.2021.0044. Epub 2021 Sep 16.

引用本文的文献

1
The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis.髓系来源抑制细胞在重症 COVID-19 发病机制中的功能作用。
Viruses. 2023 Dec 23;16(1):27. doi: 10.3390/v16010027.
2
Circulating myeloid-derived suppressor cells may be a useful biomarker in the follow-up of unvaccinated COVID-19 patients after hospitalization.循环髓系来源的抑制性细胞可能是 COVID-19 未接种疫苗患者出院后随访的一个有用的生物标志物。
Front Immunol. 2023 Nov 14;14:1266659. doi: 10.3389/fimmu.2023.1266659. eCollection 2023.
3
Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells.静脉注射卡介苗可降低新冠病毒感染的严重程度,并促进肺免疫细胞的广泛重编程。
iScience. 2023 Aug 24;26(10):107733. doi: 10.1016/j.isci.2023.107733. eCollection 2023 Oct 20.
4
The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.髓源性抑制细胞及其在癌症中的靶向治疗的最新进展
MedComm (2020). 2023 Aug 2;4(4):e323. doi: 10.1002/mco2.323. eCollection 2023 Aug.
5
Suppressive myeloid cells in SARS-CoV-2 and co-infection.抑制性髓系细胞在 SARS-CoV-2 和合并感染中的作用。
Front Immunol. 2023 Jul 20;14:1222911. doi: 10.3389/fimmu.2023.1222911. eCollection 2023.
6
Advances in the study of myeloid-derived suppressor cells in infectious lung diseases.感染性肺病中髓源性抑制细胞研究进展。
Front Immunol. 2023 Mar 29;14:1125737. doi: 10.3389/fimmu.2023.1125737. eCollection 2023.
7
Cellular immune states in SARS-CoV-2-induced disease.SARS-CoV-2 诱导疾病中的细胞免疫状态。
Front Immunol. 2022 Nov 23;13:1016304. doi: 10.3389/fimmu.2022.1016304. eCollection 2022.
8
SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.严重急性呼吸综合征冠状病毒2型感染:癌症发生和复发的一个潜在风险因素。
Int J Hematol Oncol Stem Cell Res. 2022 Apr 1;16(2):117-127. doi: 10.18502/ijhoscr.v16i2.9205.
9
Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery.新冠病毒感染对康复后固有免疫细胞特征和反应的影响。
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):993-1004. doi: 10.1016/j.jmii.2022.09.001. Epub 2022 Sep 29.
10
The function of myeloid-derived suppressor cells in COVID-19 lymphopenia.髓系来源的抑制性细胞在 COVID-19 淋巴细胞减少症中的作用。
Int Immunopharmacol. 2022 Nov;112:109277. doi: 10.1016/j.intimp.2022.109277. Epub 2022 Sep 27.